Previous close | 200.25 |
Open | 201.12 |
Bid | 201.26 x 900 |
Ask | 201.35 x 800 |
Day's range | 199.68 - 202.92 |
52-week range | 179.59 - 234.09 |
Volume | |
Avg. volume | 799,457 |
Market cap | 16.97B |
Beta (5Y monthly) | 1.00 |
PE ratio (TTM) | 43.11 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 2.88 (1.43%) |
Ex-dividend date | 28 May 2024 |
1y target est | N/A |
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the U.S. Food and Drug Administration (FDA) has approved its nAbCyte™ Anti-AAVRh74var HB-FE Assay, a companion diagnostic (CDx) to determine patient eligibility for treatment with BEQVEZ™ (fidanacogene elaparvovec-dzkt), Pfizer's recently FDA-approved hemophilia B gene therapy.
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the first quarter ended March 31, 2024 and updated full-year guidance.
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that it has been selected as the winning bidder for select assets of Invitae, a leading medical genetics company. Before the transaction can proceed, the court overseeing the process must issue an approval order following a hearing currently scheduled for May 6, 2024.